All News

Ixazomib plus daratumumab and low-dose dexamethasone yielded a high response rate and improved quality of life in frail patients with newly diagnosed multiple myeloma.

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, about genomic drivers in cholangiocarcinoma.

At ASCO 2021, Chung-Han Lee, MD, PhD, discussed an ongoing trial looking at pembrolizumab plus lenvatinib as frontline therapy for non–clear cell renal cell carcinoma.

Based on positive single-agent activity in patients with non–small cell lung cancer harboring a KRAS G12C mutation, adagrasib wins FDA breakthrough therapy designation.

The Oncologic Drugs Advisory Committee has decided to wait until more results from a clinical trial of retifanlimab are available to make a final decision about approval in squamous cell carcinoma of the anal canal.

Moreau highlighted important updates in the field of multiple myeloma, including the CARTITUDE-1 trial, which yielded promising results with ciltacabtagene autoleucel and read out at the 2021 ASCO Annual Meeting.

Shaji Kumar, MD, talks about 5-year follow-up data regarding the use of daratumumab, lenalidomide, and dexamethasone in patients with multiple myeloma who are not eligible for transplant.

Patients with long-term oropharyngeal cancer were surveyed regarding factors leading to severe effects on voice and speech.

The results of a randomized control trial emphasized the need for screening methods earlier in disease but did not show a reduction in deaths for patients with ovarian and tubal cancer.

STAR-OLZ has been found to significantly reduce adverse effects of chemotherapy-induced nausea and vomiting in clinical trials.

Usmani highlighted the FORTE study as one of the trials investigating the high-risk cohort of patients.

CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss the results of the KEYNOTE-564 trial with adjuvant pembrolizumab in patients with resected clear cell renal cell carcinoma.

Individuals with an early-onset colorectal cancer diagnosis had a survival benefit versus those at later ages, especially for patients younger than 50 years old.

Merck’s press release announced positive data from the KEYNOTE-826 trial investigating pembrolizumab plus chemotherapy with or without bevacizumab for patients with cervical cancer.

Usmani discussed the common adverse events observed from CARTITUDE-1, including hematologic events and cytokine release syndrome.

CancerNetwork® dissects an article from the journal ONCOLOGY® focusing on academic and community molecular profiling practices for patients with pancreatic adenocarcinoma.

All patients with chronic lymphocytic leukemia who were treated with zanubrutinib in the relapsed/refractory setting showed impressive responses.

Targovax announced the FDA granted fast track designation to its investigational agent ONCOS-102 for PD-1–refractory advanced melanoma.

Bayer seeks FDA approval for its agent copanlisib in combination with rituximab for the treatment of patients with indolent non-Hodgkin lymphoma.

At the 2021 ASCO Annual Meeting, Stephen Liu, MD, discussed the important of findings from the ARROW trial of pralsetinib in patients with RET-altered non–small cell lung cancer.

During the 2021 ASCO Annual Meeting, Suresh S. Ramalingam, MD, looked forward to how trials regarding adjuvant therapy for early-stage non–small cell lung cancer are poised to change the treatment paradigm in this setting.

Here are some of the important updates from last week you might have missed, including data from the 2021 ASCO Annual Meeting.

Differences in frequency of germline pathogenic variants were not seen in patient subsets by ethnicity when comparing 12 genes linked with breast cancer.

Data presented from the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials at 2021 EHA indicate success of momelotinib in extending overall survival in patients with myelofibrosis who achieve transfusion independence.

Neal D. Shore, MD, FACS, discusses the importance of multidisciplinary care for patients with advanced prostate cancer.

Petros Grivas, MD, PhD, regarding updates in genitourinary oncology that were read out at the meeting.

A trial of an eprenetapopt combination has met the prespecified primary efficacy end point in patients with acute myeloid leukemia harboring TP53 mutations.

At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

This special edition of the “Oncology Peer Review On-The-Go” podcast details treatment options and considerations for relapsed/refractory follicular lymphoma.

An expert emphasizes how a big team is needed to properly employ the different therapeutic modalities needed to treat patients with ovarian granulosa cell tumors.